- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06431893
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE) (ENSEMBLE)
Et åbent, fase 3 langsigtet forlængelsesstudie (LTE) for at vurdere sikkerheden, tolerabiliteten og effektiviteten af behandling med pegtibatinase hos deltagere med klassisk homocystinuri (HCU) på grund af cystathionin betasyntasemangel (ENSEMBLE)
The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 HARMONY are eligible to participate.
Participants will be in this clinical study for a minimum of 108 weeks including:
a treatment period of up to 104 weeks a 4-week safety follow-up period
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Overall Design:
This is a global, multicenter, single-arm, open-label study. Participants who meet all eligibility criteria may transition from other pegtibatinase studies and enroll into this LTE study for long-term safety, efficacy, and clinical assessments of pegtibatinase treatment.
All participants will follow a protocol of self-administration of pegtibatinase unless exempted. During the study, pegtibatinase pharmacokinetic assessments will be conducted. An optional protein tolerance modification (PTM) sub-study will also be conducted for eligible participants.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Adelaide, Australien
- Royal Adelaide Hospital
-
Parkville, Australien
- Royal Children's Hospital Melbourne
-
Westmead, Australien
- Westmead Hospital
-
-
-
-
-
Brussels, Belgien
- Cliniques Universitaires Saint-Luc
-
Edegem, Belgien
- Universitair Ziekenhuis Antwerpen (UZA)
-
-
-
-
-
Birmingham, Det Forenede Kongerige
- Birmingham Women's and Children's NHS Foundation Trust
-
Birmingham, Det Forenede Kongerige
- University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
-
London, Det Forenede Kongerige
- University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
-
Salford, Det Forenede Kongerige
- Salford Royal NHS Foundation Trust - Salford Royal Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85006
- Phoenix Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06519
- Yale University School of Medicine
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Maine
-
Portland, Maine, Forenede Stater, 04012
- Maine Health Pediatric Specialty Care
-
-
Maryland
-
Chevy Chase, Maryland, Forenede Stater, 20815
- Uncommon Cures
-
-
New York
-
New York, New York, Forenede Stater, 10029
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Morrisville, North Carolina, Forenede Stater, 27560
- Science 37 - Virtual Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Utah Health - The University of Utah Primary Children's Hospital
-
-
-
-
-
Paris, Frankrig
- Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
-
Tours, Frankrig
- CHRU Hôpitaux de Tours - Hôpital Bretonneau
-
Vandœuvre-lès-Nancy, Frankrig
- Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
-
-
-
-
-
Dublin, Irland
- Children's Health Ireland (CHI) at Temple Street
-
-
-
-
-
Bari, Italien
- Ospedale Pediatrico Giovanni XXIII
-
Genova, Italien
- IRCCS Istituto Giannina Gaslini
-
Milan, Italien
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
-
Monza, Italien
- Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
-
Padova, Italien
- Azienda Ospedaliera di Padova
-
-
-
-
-
Krakow, Polen
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Warsaw, Polen
- Instytut Matki i Dziecka
-
Warsaw, Polen
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
-
-
-
-
Coimbra, Portugal
- Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
-
Lisbon, Portugal
- Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
-
Porto, Portugal
- Unidade Local de Saúde de São João, EPE - Hospital São João
-
-
-
-
-
Doha, Qatar
- Hamad General Hospital
-
Doha, Qatar
- Sidra Hospital
-
-
-
-
-
Riyadh, Saudi Arabien
- King Abdullah International Medical Research Center
-
Riyadh, Saudi Arabien
- King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
-
-
-
-
-
Barcelona, Spanien
- Hospital Sant Joan de Déu
-
Madrid, Spanien
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien
- Hospital Universitario Ramón y Cajal
-
Santiago de Compostela, Spanien
- Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
-
Seville, Spanien
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Ankara, Tyrkiet (Türkiye)
- Gazi University Hospital
-
Bornova, Tyrkiet (Türkiye)
- Ege Üniversitesi Hastanesi Bornova
-
Istanbul, Tyrkiet (Türkiye)
- Istanbul University Cerrahpasa Hospital
-
-
-
-
-
Hamburg, Tyskland
- Universitätsklinikum Hamburg-Eppendorf
-
Leipzig, Tyskland
- Universitätsklinikum Leipzig
-
Münster, Tyskland
- Universitätsklinikum Münster
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
• Participants active in the COMPOSE study or who completed the 24- week blinded period on study intervention (pegtibatinase or placebo) in the Phase 3 HARMONY study
Exclusion Criteria:
• Participant permanently discontinued from study intervention treatment in a previous pegtibatinase study due to serious AE (SAE) or intolerance
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: pegtibatinase
|
Pegtibatinase BIW
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment-emergent AEs
Tidsramme: Week 1 - Week 108
|
Incidence of treatment-emergent AEs |
Week 1 - Week 108
|
|
Hypermethioninemia
Tidsramme: Week 1 - Week 108
|
Incidence of hypermethioninemia |
Week 1 - Week 108
|
|
Hypomethioninemia
Tidsramme: Week 1 - Week 108
|
Incidence of hypomethioninemia |
Week 1 - Week 108
|
|
Dietary Protein Rescue
Tidsramme: Week 1 - Week 108
|
Proportion of participants requiring dietary protein rescue for participants with hypomethioninemia |
Week 1 - Week 108
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Drug Concentration
Tidsramme: Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
Pegtibatinase pharmacokinetic parameters at steady state - maximum drug concentration [Cmax] |
Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
|
Area under the Curve within the Dosing Interval
Tidsramme: Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
Pegtibatinase pharmacokinetic parameters at steady state within the - area under the curve within the dosing interval [AUC0-tau] |
Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
|
|
Total Homocysteine (tHcy) Levels
Tidsramme: Week 1 - Week 108
|
Relative and absolute changes from baseline in tHcy levels |
Week 1 - Week 108
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Michael Imperiale, MD, Travere Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Bindevævssygdomme
- Hjernesygdomme, metaboliske, medfødte
- Hjernesygdomme, metaboliske
- Aminosyremetabolisme, medfødte fejl
- Hyperhomocysteinæmi
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Hud- og bindevævssygdomme
- Homocystinuri
Andre undersøgelses-id-numre
- TVTX-TVT058-302
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
IPD-delingstidsramme
Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
IPD-delingsadgangskriterier
Requires submission and approval of intended use and a data sharing agreement.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .